Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model

JAMA Cardiology

Volumn 2, Issue 3, 2017, Pages 305-313

  Arvanitis, Marios ^a   Koch, Clarissa M ^a   Chan, Gloria G ^a   Torres Arancivia, Celia ^a   LaValley, Michael P ^b   Jacobson, Daniel R ^a,c   Berk, John L ^a   Connors, Lawreen H ^a   Ruberg, Frederick L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; ISOLEUCINE; PREALBUMIN; RETINOL BINDING PROTEIN 4; TROPONIN I; VALINE; BIOLOGICAL MARKER; DNA; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; TRANSTHYRETIN; TTR PROTEIN, HUMAN;

AFRICAN AMERICAN; AGE; AGED; ALGORITHM; AMINO ACID SUBSTITUTION; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; GENDER; GENOTYPE; HEART AMYLOIDOSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HUMAN; INTERVENTRICULAR SEPTUM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TRANSTHYRETIN CARDIAC AMYLOIDOSIS; TTR GENE; VALIDATION STUDY; BIOPSY; BLOOD; CARDIAC MUSCLE; CARDIOMYOPATHY; DNA MUTATIONAL ANALYSIS; ELECTROCARDIOGRAPHY; EPIDEMIOLOGY; ETHNOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; FOLLOW UP; GENETICS; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; MASSACHUSETTS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

AFRICAN AMERICANS; AGED; AMYLOID NEUROPATHIES, FAMILIAL; BIOMARKERS; BIOPSY; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; DNA; DNA MUTATIONAL ANALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; MIDDLE AGED; MUTATION; MYOCARDIUM; PREALBUMIN; PROSPECTIVE STUDIES; RETINOL-BINDING PROTEINS, PLASMA; ROC CURVE; VENTRICULAR FUNCTION, LEFT;

EID: 85030484897     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.5864     Document Type: Article

References (27)

1. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222-228.e1.
2. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466-473.
3. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171-174.
4. Yamashita T, Hamidi Asl K, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005;12(2):127-130.
5. Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607-614.
6. Damy T, Costes B, Hagège AA, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37 (23):1826-1834.
7. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286-1300.
8. Berk JL, Suhr OB, Obici L, et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658-2667.
9. Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8(3):519-526.
10. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819-829.
11. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570-1579.
12. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412.
13. Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta. 2004;1703(1):1-9.
14. Wei S, Episkopou V, Piantedosi R, et al. Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. J Biol Chem. 1995;270 (2):866-870.
15. Berni R, Malpeli G, Folli C, Murrell JR, Liepnieks JJ, Benson MD. The Ile-84—>Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. J Biol Chem. 1994;269(38):23395-23398.
16. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12: 77.
17. Zhang Z. Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med. 2016;4(2):30.
18. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1-22.
19. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16(9): 965-980.
20. Team RCR. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.
21. Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid. 2015;22(1): 61-66.
22. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63.
23. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(1): 21-29.
24. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159(5):864-870.
25. Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol. 2010;5(12):1137-1146.
26. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
27. Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133(3):282-290.